Get the Stockscreener App
1.885
4.14%
0.075
After Hours:
1.90
0.015
+0.80%
Aspire Biopharma Holdings Inc stock is traded at $1.885, with a volume of 581.14K.
It is up +4.14% in the last 24 hours and down -50.34% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$1.81
Open:
$1.86
24h Volume:
581.14K
Relative Volume:
0.56
Market Cap:
$7.54M
Revenue:
-
Net Income/Loss:
$-27.39M
P/E Ratio:
-1.1218
EPS:
-1.6803
Net Cash Flow:
$-2.09M
1W Performance:
-14.71%
1M Performance:
-50.34%
6M Performance:
-88.65%
1Y Performance:
+0.00%
1-Day Range:
$1.76
$1.95
1-Week Range:
$1.71
$2.4464
52-Week Range:
$1.6547
$84.00
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.885 | 7.24M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - citizen-times.com
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - hattiesburgamerican.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - vcstar.com
Aspire Biopharma takes delivery of 2M units of BUZZ BOMB - TipRanks
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - gainesville.com
Aspire Biopharma launches brand redesign for BUZZ BOMB - TipRanks
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign - standard-journal.com
BUZZ BOMB caffeine gets sleek new look and direct-to-consumer website - Stock Titan
Aspire Biopharma files patent for first sublingual alprazolam powder By Investing.com - Investing.com Nigeria
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - columbiatribune.com
Aspire Biopharma files patent application for sublingual alprazolam formulation - TipRanks
Aspire Biopharma files patent for first sublingual alprazolam powder - Investing.com
New under-the-tongue Xanax powder aims to calm panic attacks in minutes - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - azcentral.com
Aspire Biopharma Announces Resignation of Board Director - TipRanks
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - vcstar.com
Aspire Biopharma Holdings sets share limit for stock incentive plan and approves equity award agreements - Investing.com Nigeria
Aspire Biopharma Adopts Equity Plan Limits and Award Agreements - TipRanks
Aspire Biopharma announces 1-for-40 reverse stock split By Investing.com - Investing.com Nigeria
Aspire Biopharma announces 1-for-40 reverse stock split - Investing.com
International Business Times - FinancialContent
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma director Surendra Ajjarapu resigns from board By Investing.com - Investing.com Canada
Aspire Biopharma director Surendra Ajjarapu resigns from board - Investing.com
Aspire Biopharma Approves Key Proposals at Special Meeting - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings, Inc.Common Stock (NQ: ASBP - FinancialContent
ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Nigeria
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):